Literature DB >> 36175723

Does immunotherapy change the treatment paradigm in metastatic gastric cancer?

Silvia Camera1, Nicole Liscia2, Silvia Foti2, Lavinia Barbieri3, Andrea Cossu3, Francesco Puccetti3, Ugo Elmore3, Riccardo Rosati3, Mario Scartozzi4, Elena Mazza2, Stefano Cascinu2.   

Abstract

Gastric cancer represents one of the leading causes of cancer-related death worldwide. Even if the last decade has witnessed an improvement in surgical and systemic treatments, with an increase of overall life expectancy, survival rates still remain unsatisfactory, especially for patients with metastatic disease. Systemic therapies represent the gold standard in the management of stage IV gastric cancer. In this scenario, the availability of effective second and third lines has represented for a long time the only hope to offer an overall survival improvement to these patients. Recently, the advent of immune checkpoint inhibitors has involved also gastric cancer with encouraging efficacy data in the metastatic setting, becoming integral part of the management of selected patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Clinical practice; Immunotherapy; Metastatic gastric cancer; Systemic treatment

Mesh：

Substances：

Year:  2022        PMID： 36175723     DOI： 10.1007/s12032-022-01819-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.738


  4 in total

1.  5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.

Authors:  Gokmen Umut Erdem; Yakup Bozkaya; Nuriye Yildirim Ozdemir; Nebi Serkan Demirci; Ozan Yazici; Nurullah Zengin
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

2.  Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.

Authors:  Steven B Maron; Stephanie Moya; Federica Morano; Matthew J Emmett; Joanne F Chou; Shalom Sabwa; Henry Walch; Bryan Peterson; Alexa B Schrock; Liangliang Zhang; Yelena Y Janjigian; Sree Chalasani; Geoffrey Y Ku; Umut Disel; Peter Enzinger; Nataliya Uboha; Shumei Kato; Takayuki Yoshino; Kohei Shitara; Yoshiaki Nakamura; Anwaar Saeed; Pashtoon M Kasi; Joseph Chao; Jeeyun Lee; Marinela Capanu; Zev Wainberg; Russell Petty; Filippo Pietrantonio; Samuel J Klempner; Daniel V T Catenacci
Journal:  J Clin Oncol       Date:  2022-03-29       Impact factor: 50.717

3.  Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yu-Cheng Wei; Yong-Yu Liu; Chun Chen; Ying Cheng; Rong Yin; Fan Yang; Sheng-Xiang Ren; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Jin-Ji Yang; Hong-Hong Yan; Xue-Ning Yang; Si-Yang Liu; Qing Zhou; Yi-Long Wu
Journal:  J Clin Oncol       Date:  2020-12-17       Impact factor: 44.544

4.  First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.

Authors:  Hyun Cheol Chung; Yung-Jue Bang; Charles S Fuchs; Shu-Kui Qin; Taroh Satoh; Kohei Shitara; Josep Tabernero; Eric van Cutsem; Maria Alsina; Zhu Alexander Cao; Jia Lu; Pooja Bhagia; Chie-Schin Shih; Yelena Y Janjigian
Journal:  Future Oncol       Date:  2020-11-10       Impact factor: 3.404
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.